Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series
Top Cited Papers
Open Access
- 19 June 2026
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020
- Else Kröner-Fresenius-Stiftung
- Horizon 2020 Framework Programme
This publication has 38 references indexed in Scilit:
- Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case seriesAnnals of the Rheumatic Diseases, 2026
- Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase SyndromeAnnals of the Rheumatic Diseases, 2025
- Effects of different B-cell-depleting strategies on the lymphatic tissueAnnals of the Rheumatic Diseases, 2025
- One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel diseaseAnnals of the Rheumatic Diseases, 2025
- Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantationAnnals of the Rheumatic Diseases, 2025
- Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Targeted Oncology, 2023
- Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaTargeted Oncology, 2022
- An International Multispecialty Validation Study of the IgG4‐Related Disease Responder IndexArthritis Care & Research, 2018
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessmentAutoimmunity Reviews, 2012
- International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathiesArthritis & Rheumatism, 2005